Results 91 to 100 of about 196,719 (315)

GHRHR Deficiency Enhances Retinal Ganglion Cell Survival and Visual Functions in Experimental Glaucoma by Inhibiting Ferroptosis

open access: yesAdvanced Science, EarlyView.
Glaucoma, a major cause of blindness, involves retinal ganglion cell (RGC) degeneration. This study shows growth hormone‐releasing hormone receptor (GHRHR) deficiency preserves RGC survival and restores vision, unlike activation which only aids survival.
Yan Tong   +24 more
wiley   +1 more source

Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice

open access: yesNeurobiology of Disease, 2012
Ketamine is an NMDA receptor antagonist with psychotomimetic, dissociative, amnestic and euphoric effects. When chronically abused, ketamine users display deficits in cognition and information processing, even following long-term abstinence from the drug.
Robert E. Featherstone   +5 more
doaj   +1 more source

ANKS1B in the Nucleus Accumbens Controls Escalated Cocaine Self‐Administration via Regulating CBP‐FoxO3 Complex

open access: yesAdvanced Science, EarlyView.
ANKS1B in the nucleus accumbens plays a critical role in the transition from controlled to escalated cocaine intake. Mechanistically, ANKS1B interacts with CBP to epigenetically suppress FoxO3 through H3K27 acetylation. The ANKS1B‐CBP‐FoxO3 signaling cascade presents a novel theraputic target for the treatment of cocaine addiction.
Liping Yang   +15 more
wiley   +1 more source

…such as ketamine [PDF]

open access: yesBMJ, 1996
Shewan, David   +2 more
openaire   +1 more source

S-ketamine versus racemic ketamine in dogs: their relative potency as induction agents.

open access: yes, 2014
OBJECTIVE To determine the potency ratio between S-ketamine and racemic ketamine as inductive agents for achieving tracheal intubation in dogs. STUDY DESIGN Prospective, randomized, 'blinded', clinical trial conducted in two consecutive phases.
Spadavecchia, Claudia   +5 more
core   +1 more source

Divergent Roles of mGlu2 and mGlu3 Receptors in Amyloid‐β Production and Cognitive Dysfunctions in Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
This study explores the opposing effects of the mGluR2 and mGluR3 receptors on amyloid precursor protein processing. mGluR2 promotes amyloidogenic cleavage, while mGluR3 favors non‐amyloidogenic pathways. Using a brain‐penetrant nanobody as a mGluR2 positive allosteric modulator, the study uncovers how its chronic activation aggravates amyloid‐β burden
Pierre‐André Lafon   +21 more
wiley   +1 more source

Smart Nanotechnologies for Multimodal Neuromodulation and Brain Interfacing

open access: yesAdvanced Science, EarlyView.
Recent advances in smart nanotechnologies are expanding the toolbox for brain interfacing, from wireless neuromodulation and high‐resolution sensing to targeted delivery within the central nervous system. By combining responsive nanomaterials with bioinspired design, these platforms enable multimodal interactions with neurons and glia, while also ...
Tommaso Curiale   +6 more
wiley   +1 more source

Ketamine induces apoptosis in lung adenocarcinoma cells by regulating the expression of CD69

open access: yesCancer Medicine, 2018
Ketamine, an anesthetic, analgesic, or sedative, is widely used for the treatment of cancer pain. Recently, ketamine has been also reported to be tumor repressor for inhibiting proliferation, invasion, and migration, and inducing apoptosis in many ...
Xuhui Zhou   +6 more
doaj   +1 more source

Ketamine* [PDF]

open access: yesJournal of Pain and Symptom Management, 2011
Rachel, Quibell   +4 more
openaire   +2 more sources

Reversible anesthesia of the blue duiker (Cephalophus monticola) with Medetomidine and Ketamine

open access: yes, 1995
Ten blue duiker (Cephalophus monticola) were blowdarted with a combination of ketamine and medetomidine, resulting in a level of sedation adequate for minor procedures in eight of the duikers (mean dosages: ketamine 2.2 mg/kg and medetomidine 190 µg/kg).
Wilson, K.   +3 more
core  

Home - About - Disclaimer - Privacy